Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E23.86 EPS (ttm)1.34 Insider Own0.04% Shs Outstand6.17B Perf Week-2.74%
Market Cap197.35B Forward P/E13.39 EPS next Y2.39 Insider Trans-3.65% Shs Float6.17B Perf Month-5.66%
Income8.37B PEG7.34 EPS next Q0.53 Inst Own74.10% Short Float0.82% Perf Quarter-0.62%
Sales47.92B P/S4.12 EPS this Y-14.50% Inst Trans1.05% Short Ratio1.53 Perf Half Y-5.69%
Book/sh10.83 P/B2.95 EPS next Y8.55% ROA6.50% Target Price40.27 Perf Year9.32%
Cash/sh3.35 P/C9.55 EPS next 5Y3.25% ROE15.80% 52W Range28.24 - 35.89 Perf YTD6.06%
Dividend1.12 P/FCF27.73 EPS past 5Y3.10% ROI8.90% 52W High-10.92% Beta0.90
Dividend %3.50% Quick Ratio1.30 Sales past 5Y0.10% Gross Margin81.50% 52W Low13.20% ATR0.80
Employees78300 Current Ratio1.60 Sales Q/Q-2.20% Oper. Margin30.50% RSI (14)41.96 Volatility2.31% 2.17%
OptionableYes Debt/Eq0.58 EPS Q/Q-19.00% Profit Margin22.40% Rel Volume2.56 Prev Close31.33
ShortableYes LT Debt/Eq0.44 EarningsOct 27 BMO Payout63.20% Avg Volume33.19M Price31.97
Recom2.20 SMA20-4.93% SMA50-3.39% SMA200-4.68% Volume83,430,800 Change2.04%
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Nov-25-15 04:00AM  Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products Business Wire
02:00AM  Pfizer Receives European Approval to Expand Use of XALKORI® (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer Business Wire
12:00AM  Mylan, Bruised by Failed Perrigo Bid, Set for Face-Off on Assets at Bloomberg
Nov-24-15 11:47PM  [$$] At Skadden, Tax Law Isnt So Boring as Inversions Raise the Stakes at The Wall Street Journal
11:47PM  Pfizers Allergan Deal Offers Ireland Few New Benefits at The Wall Street Journal
07:16PM  Pfizer's Allergan Deal Offers Ireland Few New Benefits at The Wall Street Journal
06:48PM  Big Fees for Pfizer-Allergan Deal at The Wall Street Journal
05:58PM  Favorite dividend plays
05:43PM  Ireland's Market Outpaces Europe As Economy Recovers at Investor's Business Daily
05:17PM  Baxalta joins biotech M&A talk
05:01PM  Veeva Systems Jumps 5%: FYQ3 Beats, Q4 View In-Line at
04:49PM  Senate Panel to Take On Inversions in Review of Global Taxation at Bloomberg
04:19PM  Pfizers Allergan Deal is an Even Bigger Tax Dodge Than Its Claiming at Fortune
04:09PM  The reason Pfizer doesn't have to care what politicians say about its $160 billion merger
04:01PM  Healthcare Sector Rebounded, Intuit Led Tech Sector to 0.73% Gain
03:29PM  Clinton Says Inversions Are Gaming the Tax System
03:16PM  Will Zoetis Derail the Allergan-Pfizer Merger? at
03:02PM  Indexes Trim Losses, Go Mixed; Exxon, Chevron, Pfizer Lead Dow at Investor's Business Daily
03:00PM  Political risk clouds Pfizer-Allergan deal at Financial Times
02:30PM  Why Are Pfizer And Allergan Talking About A Split Even Before They Merge? at Investopedia
02:19PM  [$$] Pfizer's Next Step: Break Up at The Wall Street Journal
02:18PM  Pfizer's Tax Inversion Isn't A Miracle Drug: Just Ask Monsanto And Towers Watson at Forbes
02:18PM  Pfizer's Tax Inversion Isn't A Miracle Drug: Just As Monsanto And Towers Watson at Forbes
02:14PM  Corporate tax: The $240bn black hole at Financial Times
02:04PM  Nobody really cares if Pfizer stiffs Uncle Sam
01:49PM  Obama should close Pfizer's tax loophole at Financial Times
01:45PM  Inversions divert tax dollars and undermine the USA's reputation at USA TODAY
12:56PM  Allergan represents growth, not just tax benefit
12:53PM  Tuesday links: good storytellers
12:09PM  Forget Allergan & Pfizer, Buy These Drug Stocks Instead
11:56AM  What You Need To Know About Pfizer's Tax-Driven Merger at Forbes
11:30AM  The runaway inversion craze, in three charts at CNBC
11:10AM  Pfizer, Allergan deal comes under harsh criticism (Video) at
11:01AM  Pfizer-Allergan: Why Growth At Any Price Is A Dangerous Game at Forbes
10:53AM  Allergan Deal Boosts Pfizer's Long-Term Outlook: Credit Suisse at
10:47AM  Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016 at 24/7 Wall St.
10:46AM  Markets gap down on global tensions; Pfizer controversy deepens; and Black Friday retailer tricks
10:22AM  Travel stocks drag Europe lower after Turkey downs jet at CNBC
10:10AM  Stock Market News for November 24, 2015
09:52AM  Basics of the Allergan-Pfizer Merger
09:50AM  The Allergan-Pfizer Merger: Another Big Inversion Transaction
09:44AM  Faber Report: Pfizer, Allergan follow up
09:41AM  Blame Obamacare for soaring drug costs: AEI at CNBC
09:37AM  Clinton, Trump tax comments 'a little rich': CEO at CNBC
09:30AM  Zacks Industry Outlook Highlights: Valeant, Pfizer, Allergan, AbbVie and Gilead
09:15AM  Deals of the Day: Pfizer's Future, Petco's Buyers, Activists in the News at The Wall Street Journal
09:15AM  After Pfizer-Allergan Deal, Large Inversions May Be Hard to Find
08:54AM  Here's What Pfizer Is Really Buying With Its Purchase of Allergan at Motley Fool
08:24AM  Pfizer Finally Gets What it Wants: Lower Taxes -- Podcast at The Wall Street Journal
08:23AM  Pfizer-Allergan Deal Is About Tax Inversion, Financial Engineering at TheStreet
07:41AM  This Metric Implies That It Might Be Time to Buy Big Pharma Stocks at Motley Fool
07:36AM  Russians Violate Turkish Airspace - Seconds Later - BOOM! Try the Potato/Escarole Soup
07:30AM  The 10-Point: Gerard Baker on Russian Jets, Terror Attacks, Pfizer, Back Pain and More. at The Wall Street Journal
07:04AM  How to stop Pfizers faux-Irish tax ripoff at MarketWatch
07:04AM  How to stop Pfizers faux-Irish tax ripoff
06:32AM  Ask Matt: Is Pfizer a better investment now? at USA TODAY
05:16AM  Politicians slam tax-avoiding Pfizer-Allergan deal Reuters
05:16AM  Germany's Schaeuble says need to ensure tax base doesn't erode Reuters
01:31AM  PRESS DIGEST - Wall Street Journal - Nov 24 Reuters
12:44AM  PRESS DIGEST- New York Times business news - Nov 24 Reuters
12:33AM  [$$] Pfizer and Allergan: How the Deal Adds Up at The Wall Street Journal
12:30AM  [$$] Pfizer Weighs Splitting Up New Drug Behemoth at The Wall Street Journal
12:28AM  [$$] Pfizer Inversion Puts Pressure on U.S. Lawmakers to Revamp Tax Rules at The Wall Street Journal
Nov-23-15 10:42PM  Most Asian stock markets lower as commodity slump weighs
08:45PM  U.S. politicians slam tax-avoiding Pfizer-Allergan deal Reuters
08:38PM  What the Merger of Pfizer and Allergan Means for R&
08:26PM  [$$] Pfizer Weighs Splitting Up New Drug Behemoth at The Wall Street Journal
08:24PM  Pharma ETFs Pop Amid Pfizer-Allergan $160 Bil Deal at Investor's Business Daily
08:17PM  Experts: U.S. unlikely to block Pfizer-Allergan deal at USA TODAY
07:52PM  Things to know about corporate inversion AAP
07:26PM  5 global drugmakers pay the lowest taxes at USA TODAY
07:08PM  Cramer Remix: The newest king of the food aisle at CNBC
07:00PM  The top Mergers of 2015
06:52PM  Pfizer seeks Washington support for $160bn Allergan deal at Financial Times
06:49PM  Pfizer to buy Allergan in $160 billion deal Reuters
06:22PM  Cramer: Can Pfizer reinvent itself with Allergan? at CNBC
06:22PM  Why Pfizer's talking about breaking up on the same day it announced a $160 billion merger
06:17PM  Republican Trump calls Pfizer deal to move tax base overseas 'disgusting' Reuters
06:02PM  U.S. Republican Trump calls Pfizer deal to move tax base overseas 'disgusting' Reuters
06:00PM  Market dislikes Allergan-Pfizer deal: Cramer
05:59PM  Fast Money final trade: F, PFE, TLT & AA
05:42PM  Stocks give up an early gain and end lower; GameStop sinks at Los Angeles Times
05:32PM  PFIZER INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers,
05:31PM  Politicians slam tax-avoiding Pfizer-Allergan mega-deal Reuters
05:29PM  Like Drug Companies, Big Chipmakers Are Planning To Spend On M&A Instead of R&D at Forbes
05:23PM  Pfizer, Allergan Seal $160 Billion Tax-Inversion Deal at Investor's Business Daily
05:19PM  Digital downloads weigh on GameStop at Financial Times
05:17PM  Business Highlights
05:15PM  [$$] Pfizer Investors Face a Tax Hit at The Wall Street Journal
05:00PM  Stocks End Modestly Lower; Pfizer Deal Eyed
04:57PM  $160B deal to combine Pfizer and Allergan raises outcry
04:53PM  [$$] Pfizer Inversion Pressures Tax-Rule Revamp at The Wall Street Journal
04:45PM  Stocks end slightly lower; consolidate previous weeks big gains at MarketWatch
04:42PM  US STOCKS-Wall St falls after strong week; Pfizer and Allergan drag
04:35PM  [$$] Pfizer and Allergan: How the Deal Adds Up at The Wall Street Journal
04:29PM  Pfizer and Chipotle are big market movers
04:28PM  Stocks Slip as Oil Prices Drop at TheStreet
04:27PM  Stocks slip after year's biggest week of gains at USA TODAY
04:24PM  Merger With Pfizer Could Boost Allergan's Credit Rating at
04:20PM  Pfizer and Allergan merge in $160B tax inversion deal at USA TODAY
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins; and license and collaboration agreement with Servier to develop and commercialize UCART19. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM
HILL CHARLES HExecutive Vice PresidentMay 29Sale34.9242,8701,497,02069,357Jun 02 04:54 PM
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM